12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Company News  |  Deals

Seattle Genetics, Bayer deal

Seattle granted Bayer's Bayer Healthcare LLC subsidiary worldwide rights to use Seattle's auristatin-based antibody-drug conjugate (ADC) technology with undisclosed antibodies to multiple undisclosed cancer...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >